28,000-share stock option grant to LeonaBio (LONA) director

Rhea-AI Filing Summary

LeonaBio, Inc. director Michael A. Panzara received a grant of stock options covering 28,000 shares of common stock, with an exercise price of $9.54 per share and expiration on April 8, 2036. These options were granted at no upfront cost as compensation, not through an open-market purchase.

According to the grant terms, the 28,000 option shares are scheduled to vest in equal monthly installments over 24 months from the grant date, as long as Panzara continues to serve as a “Service Provider” under LeonaBio’s 2026 Equity Incentive Plan. Following this grant, he holds 28,000 derivative securities tied to LeonaBio common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Panzara Michael A.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	28,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 28,000 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 28,000 shares Exercise price: $9.54 per share Expiration date: April 8, 2036 +2 more

5 metrics

Option grant size 28,000 shares Stock Option (Right to Buy) granted to director

Exercise price $9.54 per share Conversion or exercise price of stock option

Expiration date April 8, 2036 Option expiration for 28,000-share grant

Vesting schedule 24 monthly installments Vests monthly over 24 months from grant date

Post-transaction derivative holdings 28,000 options Total derivative securities following transaction

Key Terms

Stock Option (Right to Buy), 2026 Equity Incentive Plan, Service Provider, Grant, award, or other acquisition

4 terms

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

2026 Equity Incentive Plan financial

"as defined in the Issuer's 2026 Equity Incentive Plan"

Service Provider financial

"subject to the optionee continuing to be a Service Provider"

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Panzara Michael A.

(Last) (First) (Middle)

C/O LEONABIO, INC.

18706 NORTH CREEK PARKWAY, SUITE 104

(Street)

BOTHELL WASHINGTON 98011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LeonaBio, Inc. [ LONA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.54	04/09/2026		A		28,000		(1)	04/08/2036	Common Stock	28,000	$0	28,000	D

Explanation of Responses:

1. The shares subject to the option shall be scheduled to vest monthly over a term of 24 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.

	/s/ Mark Worthington, Attorney in fact for Michael A. Panzara	04/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did LeonaBio (LONA) director Michael Panzara report on this Form 4?

Michael A. Panzara reported receiving a stock option grant for 28,000 shares of LeonaBio common stock. The options were granted as compensation, not purchased in the market, and give him the right to buy shares at a fixed exercise price.

How many LeonaBio (LONA) shares are covered by Michael Panzara’s option grant?

The option grant covers 28,000 shares of LeonaBio common stock. These are derivative securities, meaning they represent the right to buy shares in the future rather than current share ownership, subject to vesting and exercise conditions.

What is the exercise price and expiration date of Michael Panzara’s LeonaBio options?

The stock options have an exercise price of $9.54 per share and expire on April 8, 2036. This means Panzara can choose to buy LeonaBio shares at $9.54 any time before that expiration date, once the options have vested.

How do Michael Panzara’s LeonaBio stock options vest over time?

The 28,000 options vest in equal monthly installments over 24 months following the grant date. Vesting is conditioned on Panzara continuing as a “Service Provider” under LeonaBio’s 2026 Equity Incentive Plan throughout the applicable monthly vesting dates.

Did Michael Panzara buy or sell any LeonaBio (LONA) shares in the market?

The Form 4 reflects a grant of stock options, not an open-market trade. The transaction code is a grant or award acquisition, so there were no market purchases or sales of LeonaBio common stock reported in this filing.

What are Michael Panzara’s LeonaBio derivative holdings after this Form 4 transaction?

After the reported transaction, Panzara holds 28,000 derivative securities in the form of stock options linked to LeonaBio common stock. These options may convert into shares in the future if he chooses to exercise them after they vest.